Since anti-ACE2 IgM autoantibodies have features of T cell–independent responses, this may provide an important opportunity to use short-term immune-focused therapies in incipient severe COVID-19 (consistent with the dexamethasone results; ref. 12) rather than the deeper immunosuppression needed for T cell–driven processes. The gene discussed is ACE2; the disease is COVID-19.